Nasdaq:OSUR
OraSure Technologies Provides Update on Its Emergency Use Authorization Application for Its Lab-based Oral Fluid SARS-CoV-2 Antibody Test Nasdaq:OSUR
BETHLEHEM, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today disclosed that the U.S. Food and Drug Administration (FDA) has requested additional information as part of its review of the Company’s application for Emergency Use Authorization (EUA) for its laboratory-based oral …
OraSure Technologies, Inc. Announces Third Quarter 2020 Financial Results and Provides Update on COVID-19 Developments Nasdaq:OSUR
Net Third Quarter Revenues of $48.0 Million Increased 33% Year-Over-Year, Driven by $18.4 Million in Sales of Oral Fluid Collection Devices for COVID-19 Molecular Testing Company Has Submitted EUA Application For Its Lab-based Oral Fluid SARS-CoV-2 Antibody Test Management to Host Conference Call and Webcast Today at 5:00 p.m. ET BETHLEHEM, Pa., Nov. 04, 2020 …
OraSure Technologies, Inc. Prices Underwritten Offering of Common Stock Nasdaq:OSUR
BETHLEHEM, Pa., June 02, 2020 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (Nasdaq: OSUR) (“OraSure” or the “Company”) today announced the pricing of an underwritten offering of 8,000,000 shares of its common stock at a price of $11.00 per share. After the underwriting discount and estimated offering expenses, OraSure expects to receive net proceeds of approximately …
